Lead-212 supply pact links Eckert & Ziegler, Thor Medical
hor Medical will initially supply Pb-212 to Eckert & Ziegler for preclinical R&D, while the companies explore broader isotope-production and radiopharmaceutical-manufacturing integration.
Eckert & Ziegler and Thor Medical have signed a collaboration and supply agreement focused on lead-212 for targeted alpha therapy development. The companies said the agreement is intended to strengthen the supply and manufacturing base for Pb-212-based radiopharmaceutical programs.
Under the agreement, Thor Medical will initially supply lead-212 to Eckert & Ziegler for preclinical research and development. The companies will also evaluate how to combine Thor Medical’s isotope-production capabilities with Eckert & Ziegler’s radiopharmaceutical manufacturing infrastructure.
Pb-212 is being developed as an alpha-emitting isotope for targeted cancer therapies. Eckert & Ziegler said the isotope has drawn interest because of its in-body chemistry, clearance profile, and potential use in theranostic applications.
Thor Medical’s technology platform has been developed and validated through pilot operations at Herøya Industrial Park in Norway since early 2024. The company said it has delivered products to industry customers since 2025.
AlphaOne, Thor Medical’s first commercial production facility, is now in commissioning and is expected to begin production in Q3 2026. A 2025 final-investment-decision release put the plant’s estimated capital expenditure at NOK 200M.
The AlphaOne plant is expected to reach 15,000 patient doses after 3 years of operations and 25,000 patient doses after 5 years, without additional capital expenditure, according to Thor Medical’s 2025 project announcement.
Thor Medical reported in February that AlphaOne was on time and on budget, with Q3 production planned. The company also said its order backlog had reached approximately NOK 850M through multiyear sales agreements with new and existing customers.
Eckert & Ziegler said it combines radioisotope supply with radiopharmaceutical research, development, manufacturing, and distribution services. The company also said its CDMO services are designed for biotech and pharmaceutical firms that lack in-house radiopharmaceutical production capacity.
Company:Thor Medical
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Aidoc creates growth post for enterprise AI push
Christopher Young will lead global expansion, partnerships, and enterprise growth after prior healthcare technology roles at BCG and Ascension.
Everlight shifts global teleradiology stack to RadOS
The 5-year agreement will put Sirona Medical’s cloud-native platform across Everlight’s operations in 6 markets, covering PACS, reporting, worklist, archive, and AI workflows.
HCA’s CHCP deal includes imaging CE provider MTMI
HCA Healthcare agreed to acquire CHCP, a Texas allied-health education provider that owns MTMI and offers programs in sonography, radiologic technology, and medical coding.
CBCT perfusion collaboration targets stroke angio suite
Siemens Healthineers and Cercare Medical are pairing Syngo DynaCT Multiphase with Neurosuite to support perfusion imaging during acute stroke interventions.
Pathology support broadens MedDream viewer scope
Version 8.9.0 is scheduled for June 2026 through aycan and will add support for pathology workflows and saving reconstructed MPR viewports as new study series.
DOSIsoft unit gives PLANET a theranostics focus
DOSIsoft Theranostics will operate within the DOSIsoft group, with its own partnerships and investment strategy centered on PLANET software.
Vault-ready proton system headed to Tam Anh
Mevion said the S250-FIT installation would be Vietnam’s first proton therapy system, with operation expected as early as late 2027 at Tam Anh’s Phu My Hung facility.
I-MED sale gives Jardines 215-clinic radiology network
Jardine Matheson will acquire 100% of I-MED Radiology Network in a deal valued at A$3.4B, including I-MED’s minority stake in Harrison.ai.
Expected Russell addition puts Hyperfine in small-cap benchmarks
FTSE Russell’s preliminary June reconstitution list includes Hyperfine, with index changes set to take effect after U.S. markets close on June 26.
Curium approach puts Lantheus deal value near $7B
Lantheus is weighing a potential sale after an approach from Curium Pharma, while company filings show recent Pylarify pressure and pending PET regulatory milestones.
GE HealthCare to distribute NordicNeuroLab fMRI tools
The agreement covers nordicMEDiVA, nordicAktiva, selected MRI hardware, and patient comfort products across authorized global markets.
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.